Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds-Reference-Cited by-同舟云学术

Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug‐like compounds

Published:2013-06-05 Issue:7 Volume:5 Page:1103-1118
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Cherry Jonathan J.¹²,Osman Erkan Y.³⁴,Evans Matthew C.²,Choi Sungwoon⁵,Xing Xuechao⁵,Cuny Gregory D.⁵,Glicksman Marcie A.⁵,Lorson Christian L.³⁴,Androphy Elliot J.¹²

Affiliation:

1. Department of MedicineUniversity of Massachusetts Medical SchoolWorcesterMAUSA

2. Derpartment of DermatologyIndiana University School of MedicineIndianapolisINUSA

3. Department of Veterinary PathobiologyBond Life Sciences CenterUniversity of MissouriColumbiaMOUSA

4. Department of Molecular Microbiology and ImmunologyUniversity of Missouri School of MedicineColumbiaMOUSA

5. Laboratory for Drug Discovery in NeurodegenerationHarvard NeuroDiscovery CenterBrigham and Women's Hospital and Harvard Medical SchoolCambridgeMAUSA

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/emmm.201202305

Reference98 articles.

1. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients

2. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

3. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy

4. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

5. Stimulating Full-Length SMN2 Expression by Delivering Bifunctional RNAs via a Viral Vector

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells;Molecular and Cellular Biochemistry;2022-10-27

2. History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy;Frontiers in Cellular Neuroscience;2022-08-12

3. A Chemical Biology Perspective to Therapeutic Regulation of RNA Splicing in Spinal Muscular Atrophy (SMA);ACS Chemical Biology;2022-05-31

4. Catalytic Asymmetric Hydrogenation of 3-Ethoxycarbonyl Quinolin-2-ones and Coumarins;Organic Letters;2021-04-19

5. Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals;Current Gene Therapy;2021-02-09